The U.S. Food and Drug Administration has initiated a recall after identifying current Good Manufacturing Practice (CGMP) deviations. The specific issue involved intermittent exposure to temperature excursions during product storage, which may affect product quality and safety.
Manufacturers are advised to assess affected batches and implement corrective actions to prevent future occurrences.
Cập nhật pháp chế24 thg 8, 2026•1 phút đọc
FDA Recall: CGMP Deviations Due to Intermittent Temperature Excursions
The FDA has issued a recall citing CGMP deviations caused by intermittent temperature excursions during storage.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: FDA.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá